[{"id":"c4c56e6e-4ee3-401a-9d0b-1b97e1809f91","acronym":"","url":"https://clinicaltrials.gov/study/NCT02666105","created_at":"2021-01-18T12:59:48.229Z","updated_at":"2024-07-02T16:35:46.877Z","phase":"Phase 2","brief_title":"Exemestane in Post-Menopausal Women With NSCLC","source_id_and_acronym":"NCT02666105","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ER • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement • EGFR rearrangement","tags":["ER • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement • EGFR rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2023-05-31"},{"id":"0a94fe0d-06f9-4f68-bbfc-471016e0ccc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04460729","created_at":"2021-01-18T21:26:50.446Z","updated_at":"2024-07-02T16:36:37.846Z","phase":"Phase 2","brief_title":"A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases","source_id_and_acronym":"NCT04460729","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET mutation • EGFR rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET mutation • EGFR rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2020-12-03"},{"id":"6f59b423-d252-4549-aefd-b391ba3f1d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02495636","created_at":"2021-01-18T12:02:02.112Z","updated_at":"2024-07-02T16:37:20.748Z","phase":"Phase 2","brief_title":"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02495636","lead_sponsor":"Yale University","biomarkers":" ALK • CTAG1B","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement","tags":["ALK • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2017-06-22"}]